0001209191-18-061329.txt : 20181206
0001209191-18-061329.hdr.sgml : 20181206
20181206170634
ACCESSION NUMBER: 0001209191-18-061329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181127
FILED AS OF DATE: 20181206
DATE AS OF CHANGE: 20181206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Watts Ryan J.
CENTRAL INDEX KEY: 0001724310
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 181221415
MAIL ADDRESS:
STREET 1: C/O DENALI THERAPEUTICS INC.
STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-27
0
0001714899
Denali Therapeutics Inc.
DNLI
0001724310
Watts Ryan J.
C/O DENALI THERAPEUTICS INC.
151 OYSTER POINT BOULEVARD, SECOND FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
12505
D
Common Stock
2018-11-27
5
G
0
E
40000
0.00
D
2689304
I
See footnote
Common Stock
2018-12-03
4
S
0
17933
18.4171
D
2671371
I
See footnote
Common Stock
2018-12-03
4
S
0
400
19.16
D
2670971
I
See footnote
The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund.
The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.05 to $18.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Tyler Nielsen, by power of attorney
2018-12-06